Compensatory weight gain due to dopaminergic hypofunction: new evidence and own incidental observations by Reinholz, Julia et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Nutrition & Metabolism
Open Access Commentary
Compensatory weight gain due to dopaminergic hypofunction: new 
evidence and own incidental observations
Julia Reinholz*1, Oliver Skopp1,2, Caterina Breitenstein, Iwo Bohr1, 
Hilke Winterhoff2 and Stefan Knecht1
Address: 1Department of Neurology, University of Muenster, Albert-Schweitzer-Strasse 33, 48129 Muenster, Germany and 2Department of 
Pharmacology and Toxicology, University of Muenster, Domagkstrasse 12, 48149 Muenster, Germany
Email: Julia Reinholz* - reinhj@uni-muenster.de; Oliver Skopp - oskopp@uni-muenster.de; Caterina Breitenstein - caterina.breitenstein@uni-
muenster.de; Iwo Bohr - iwo.bohr@uni-muenster.de; Hilke Winterhoff - winterh@uni-muenster.de; Stefan Knecht - knecht@uni-muenster.de
* Corresponding author    
Abstract
There is increasing evidence for a role of dopamine in the development of obesity. More
specifically, dopaminergic hypofunction might lead to (over)compensatory food intake. Overeating
and resulting weight gain may be induced by genetic predisposition for lower dopaminergic activity,
but might also be a behavioral mechanism of compensating for decreased dopamine signaling after
dopaminergic overstimulation, for example after smoking cessation or overconsumption of high
palatable food. This hypothesis is in line with our incidental finding of increased weight gain after
discontinuation of pharmaceutical dopaminergic overstimulation in rats. These findings support the
crucial role of dopaminergic signaling for eating behaviors and offer an explanation for weight-gain
after cessation of activities associated with high dopaminergic signaling. They further support the
possibility that dopaminergic medication could be used to moderate food intake.
Background
Eating and dopaminergic signaling are closely related.
Food reward and food-reward associated stimuli both ele-
vate dopamine levels in crucial components of the brain
reward circuits [1,2]. In fact, food might be the most
important natural stimulator of the reward system in the
brain [3]. Therefore, overeating may represent an attempt
to compensate for hedonic reward deficiency under con-
ditions of reduced dopaminergic activity.
Relative dopaminergic deficiency can be caused by differ-
ent conditions, for example genetic predisposition or after
adaptive downregulation of the dopaminergic system due
to preceding overstimulation. Thus, substitutional food
intake might explain weight gain after smoking cessation,
during antipsychotic medication and in obesity.
A rebound effect of eating behavior after dopaminergic
overstimulation could account for the weight gain often
associated with smoking cessation, because during smok-
ing, nicotine excites dopamine-containing cells in the ven-
tral tegmental area, resulting in dopamine release in
mesolimbic and mesocortical projections [4].
Additionally, an increase in body weight is a side effect of
many commonly used drugs. Particularly, antidopaminer-
gically acting neuroleptics, tricyclic antidepressants, lith-
ium, and some anticonvulsants contribute to weight gain.
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To date, the underlying mechanisms are still poorly
understood although interactions with the dopamine sys-
tem have been implicated [5].
Similarly, in obesity body mass index is negatively corre-
lated with D2 receptor density in the striatum [6,7], which
might reflect neuroadaptation secondary to overstimula-
tion with palatable food [8,9]. Thus, increased food intake
may be a compensatory behavior for low dopaminergic
drive [10]. Stice et al. recently reported that lower striatal
activation in response to food intake was associated with
obesity. Furthermore, this relation was modulated by
genetically determined D2 receptor availability [11].
These results are in line with our own incidental observa-
tion of increased body weight after pharmaceutical
dopaminergic overstimulation in an animal model. Regu-
lation of feeding by acute dopaminergic stimulation has
already been demonstrated [e.g. [12]], but rebound effects
after overstimulation have not been reported. Food
restricted rats received the dopamine precursor levodopa
over five days and were then withdrawn from dopaminer-
gic medication. Subsequently, animals were allowed to
feed ad libitum. Over the next 12 weeks the intervention
group gained 15% more weight than the vehicle group (p
< 0.01) and continued to be heavier at 16 week follow-up
(p < 0.05, see Figure 1 and Figure 2).
Discussion
There is growing evidence for a role of dopaminergic sig-
naling in the development of obesity. Compensatory eat-
ing due to hypofunctionality of the dopaminergic system
can not only be based on genetically determined factors,
but might also be induced by preceding overstimulation
with natural stimulation or pharmacological enhance-
ment. The later was demonstrated by our incidental find-
ing that a decreased dopaminergic tone (relative to a
preceding period of extrinsically elevated dopaminergic
drive) enhanced weight gain after a period of food depri-
vation.
While acute administration of levodopa in combination
with carbidopa leads to an increase in brain dopamine
levels [13,14], diminished dopaminergic responses to
Effects of L-DOPA treatment on body weight Figure 1
Effects of L-DOPA treatment on body weight. Rats treated previously with L-DOPA had the same weight as rats treated 
with a vehicle solution before and immediately after the treatment, but gained more weight during a follow-up period. Results 
represent the means ± SD of body weight for each group measured at the respective time point. Asterisk indicates a significant 
difference (p < 0.05).Nutrition & Metabolism 2008, 5:35 http://www.nutritionandmetabolism.com/content/5/1/35
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external stimulation have been observed after repeated
levodopa administration [15-17]. (Over)stimulation of
the dopaminergic system by intake of dopaminergic sub-
stances or chronic overconsumption of food [10], leads to
adaptational processes in the dopaminergic system
[18,19]. This downregulation is likely to be complex and
seems to involve decreased dopamine synthesis [20], and
decreased post-synaptic receptor expression [21,22]. In
addition to hedonic or motivational changes in response
to food, interactions of the dopaminergic system with adi-
posity signals might have induced changes in feeding
behavior [see [23] for review]. We assume that in our
study the hyperdopaminergic state during the repeated
levodopa administration induced a hypodopaminergic
state after drug discontinuation, which resulted in
rebound effects of weight gain as a compensatory mecha-
nism [3].
Dopaminergic modulation of such rebound effects can
explain weight-gain after cessation of activities associated
with high dopaminergic signaling. Additionally, they
offer explanations for individual differences and pharma-
cological treatment related to post-smoking weight-gain.
For instance, in smokers with dopamine receptor poly-
morphism variants associated with lower dopamine drive,
food seems to have greater reinforcing effects as indicated
by an increased weight gain after smoking cessation rela-
tive to individuals without this variant [24,25].
Our results also raise the possibility that dopaminergic
medication may be helpful in preventing compensatory
food intake and offer a potential pharmacological treat-
ment of obesity [26]. Increased food reinforcement and
weight gain in ex-smokers can be attenuated by bupro-
pion, a dopamine and norepinephrine reuptake inhibitor
that raises brain dopamine levels and increases receptor
activation [27]. Similarily, after an increase in brain syn-
aptic dopamine via pharmacological inhibition of the
dopamine transporter, obese men reduced their energy
intake by one third compared to placebo during a meal of
highly palatable food [28]. On the other hand dopamin-
ergic treatment in Parkinson's disease or Restless Legs Syn-
drome may be associated with the inverse effect, i.e. an
unwanted weight loss [29].
Conclusion
Our findings support evidence of dopaminergically
induced eating behavior to compensate for low dopamin-
ergic signaling. They should alert us to the possibility that
overeating after withdrawal might be a potential side-
effect of dopaminergic stimulation. On the other hand,
our results also raise the possibility that dopaminergic
medication may be helpful in preventing compensatory
food intake. These possibilities and limitations of
dopaminergic stimulation on motivation merit further
investigation.
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